@article{ac023c33b8a74daa8d19bb41f2b24bc9,
title = "PET‐CT Imaging of Polymeric Nanoparticle Tumor Accumulation in Patients",
abstract = "Several FDA/EMA-approved nanomedicines have demonstrated improved pharmacokinetics and toxicity profiles compared to their conventional chemotherapeutic counterparts. The next step to increase therapeutic efficacy depends on tumor accumulation, which can be highly heterogeneous. A clinical tool for patient stratification is urgently awaited. Therefore, a docetaxel-entrapping polymeric nanoparticle ( 89Zr-CPC634) is radiolabeled, and positron emission tomography/computed tomography (PET/CT) imaging is performed in seven patients with solid tumors with two different doses of CPC634: an on-treatment (containing 60 mg m −2 docetaxel) and a diagnostic (1–2 mg docetaxel) dose (NCT03712423). Pharmacokinetic half-life for 89Zr-CPC634 is mean 97.0 ± 14.4 h on-treatment, and 62.4 ± 12.9 h for the diagnostic dose (p = 0.003). At these doses accumulation is observed in 46% and 41% of tumor lesions with a median accumulation in positive lesions 96 h post-injection of 4.94 and 4.45%IA kg −1 (p = 0.91), respectively. In conclusion, PET/CT imaging with a diagnostic dose of 89Zr-CPC634 accurately reflects on-treatment tumor accumulation and thus opens the possibility for patient stratification in cancer nanomedicine with polymeric nanoparticles. ",
keywords = "PET/CT imaging, Zr, cancer, docetaxel, nanomedicines, polymeric nanoparticles, solid tumors",
author = "IHC Miedema and GJC Zwezerijnen and MC Huisman and Ellen Doeleman and Mathijssen, {Ron H. J.} and Twan Lammers and Qizhi Hu and {van Dongen}, G* and Cristianne Rijcken and DJ Vugts and Menke, {C. W.}",
note = "Funding Information: The authors like to acknowledge the significant contributions of Jimmy Weterings on the design and actual synthesis of BCN-desferal and Rob Hanssen for all (pre)clinical study support, both employees of Cristal Therapeutics at the time of study execution. This study was supported by Health Holland and financial contributions of Cristal Therapeutics (CT). CT participated in the design, study conduct, analysis, and interpretation of the data and approval of this manuscript. Funding Information: The authors like to acknowledge the significant contributions of Jimmy Weterings on the design and actual synthesis of BCN‐desferal and Rob Hanssen for all (pre)clinical study support, both employees of Cristal Therapeutics at the time of study execution. This study was supported by Health Holland and financial contributions of Cristal Therapeutics (CT). CT participated in the design, study conduct, analysis, and interpretation of the data and approval of this manuscript. Funding Information: C.R. and Q.H. are employees of Cristal Therapeutics. C.W.M. and R.M. received research funding from Cristal Therapeutics. The authors declare that they have no other competing interests. Publisher Copyright: {\textcopyright} 2022 The Authors. Advanced Materials published by Wiley-VCH GmbH.",
year = "2022",
month = may,
day = "26",
doi = "https://doi.org/10.1002/adma.202201043",
language = "English",
volume = "34",
journal = "Advanced materials",
issn = "0935-9648",
publisher = "Wiley-VCH Verlag",
number = "21",
}